Best peptide telehealth programs: why we do not rank them yet

Why there is no ranking

Our provider ranking covers compounded GLP-1 programs, where we read each program’s prices on its own pages. Our October 15, 2026 price index contains only tirzepatide and semaglutide rows; it has no peptide rows. A ranking of peptide programs would need the same standard: price, plan terms, named pharmacy and legal basis, read at source and dated. We do not have that yet.

There is also a legal problem a ranking would hide. A program can be well run and still sell BPC-157, which has no established compounding route as of October 15, 2026. Ranking it highly would imply a legitimacy the substance does not have.

What we did read on October 15, 2026

These reads are not a ranking and not an endorsement. Note that Oak markets tesamorelin for “healthy body composition”, while the only approved tesamorelin product, Egrifta WR, is indicated for abdominal fat in adults with HIV and lipodystrophy and “not indicated for weight loss management.”

The checklist a program must pass

1. Named clinician, licensed in your state, who can decline you.
2. Named pharmacy with a licence you can look up, and its legal basis for compounding each substance in writing.
3. Substance status disclosed: approved, Category 1, or no established route — said plainly.
4. Evidence claims that separate human trials from animal studies and blood markers.
5. Total price read on its own page: medication, membership, consults, labs and supplies.
6. Cancellation and refund terms published before checkout.
7. No research-use products or links to research sellers.
8. Anti-doping warning for athletes, since most growth-hormone peptides are prohibited by WADA.

Run it yourself with our provider verification guide.

Choose the substance before the program

Start with our peptide status table. If the substance is BPC-157, TB-500, CJC-1295 or ipamorelin, no program can offer a lawful compounded version as of October 15, 2026. If it is NAD+ or glutathione, Category 1 applies. If it is tesamorelin, ask whether you will get Egrifta WR or a compounded product. For sermorelin, see its unresolved status.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For programs: if the interim access policy is published, some programs will start offering peptides they could not lawfully offer before. We will add first-party reads when that happens; until then this page stays a checklist.